8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 2, 2007

SCIVANTA MEDICAL CORPORATION

(Exact name of registrant as specified in charter)

Nevada	000-27119	22-2436721
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
215 Morris Avenue, Spring Lake, New Jersey			07762
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (732) 282-1620

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 - Other Information

Item 8.01.Other Events.

On August 2, 2007, Scivanta Medical Corporation issued a press release announcing that its common stock has commenced quotation on the Over-the-Counter Bulletin Board under the trading symbol OTC Bulletin Board: SCVM. A copy of the press release is attached hereto as Exhibit 99.1.

Section 9 - Financial Statements and Exhibits

Item 9.01.Financial Statements and Exhibits.

(d)Exhibits:

Exhibit
Number	Description
99.1	Press Release Re: Scivanta Medical Corporation Moves from Pink Sheets to OTC Bulletin Board

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCIVANTA MEDICAL CORPORATION

(Registrant)

By: /s/ David R. LaVance                            

David R. LaVance

Chairman of the Board, President and

Chief Executive Officer

Date: August 2, 2007

3

EXHIBIT INDEX

Exhibit
Number	Description
99.1	Press Release Re: Scivanta Medical Corporation Moves from Pink Sheets to OTC Bulletin Board

EX-99.1

EXHIBIT 99.1

SCIVANTA MEDICAL CORPORATION MOVES FROM PINK SHEETS

TO OTC BULLETIN BOARD

Company Commences Trading on OTC Bulletin Board

SPRING LAKE, N.J. - August 2, 2007 - Scivanta Medical Corporation (OTCBB: SCVM) today announced that its common stock commenced trading on the Over-the-Counter (OTC) Bulletin Board under the symbol SCVM.OB. Previously, Scivanta’s common stock traded through the Pink Sheets.

David LaVance, President and Chief Executive Officer of Scivanta commented, “As Scivanta moves forward with the development and commercialization of the Hickey Cardiac Monitoring System (HCMS) and pursues other corporate opportunities, we feel it is necessary to take the appropriate measures to make sure our common stock is more available to those interested in our potential.” LaVance continued, “In this instance, we found it beneficial for our common stock to be included for quotation on the OTC Bulletin Board. We believe this will increase the liquidity of our common stock and make our shares of common stock more readily available to potential investors.”

About Scivanta Medical Corporation

Scivanta is focused on acquiring and developing medical technologies and products which offer advantages over available medical procedures and treatments. The company has acquired the exclusive worldwide rights to develop, make and sell certain proprietary technologies known as the Hickey Cardiac Monitoring System, a minimally-invasive two-balloon esophageal catheter system used to monitor cardiac performance. The HCMS is expected to provide the primary measurements of cardiac performance in a minimally invasive and cost-effective manner and is designed to be used outside of an intensive care setting. The HCMS is currently under development and must receive the appropriate regulatory approvals prior to commercialization. As Scivanta develops the HCMS, it expects to continue to review for acquisition other medical technologies and products that are sold, or capable of being sold, in a specialty or niche market.

Forward-Looking Statements

Statements about the Scivanta's future expectations and all other statements in this press release other than historical facts are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from expected results. Among these risks, trends and uncertainties are economic conditions both generally and within the industries in which Scivanta may participate; competition within Scivanta's chosen industries, including competition from much larger competitors; technological advances; available capital; regulatory approval; and failure by Scivanta to successfully develop or acquire products and form new business relationships. Scivanta intends that such forwarding-looking statements shall be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Scivanta's actual results could differ materially from expected results.

Scivanta Medical Corporation

Tom Gifford, Chief Financial Officer

(732) 282-1620 x15

Fax: (732) 282-1621

The Investor Relations Group

Investor Relations

Dan Berg/Joseph Kessler

(212) 825-3210

Media Relations

Bill Douglass

(212) 825-3210